3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
13
Recruiting
6
Unknown
2
Terminated
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
13
Gynecologic
10
Breast
10
Other solid neoplasm
5
Thoracic
4
Gastrointestinal
3
Tumor-Agnostic
2
Other hematologic neoplasm
2
Lymphoid
2
Plasma cell
1
Myeloid
1
Endocrine
1
Dermatologic
1
Classical hematology
1
Conditions
Neoplasms
2
Interventions
Gemcitabine
13
pembrolizumab
12
Capecitabine
9
Irinotecan
8
Erlotinib Hydrochloride
8
Carboplatin
8
Blood Specimen Collection
8
Nivolumab
7
Docetaxel
7
Cisplatin
7
Cetuximab
7
Paclitaxel
6
Everolimus
6
130-nm albumin-bound paclitaxel
6
vadimezan
5
Magnetic Resonance Spectroscopy
5
Fluorouracil
5
Cyclophosphamide
5
trametinib
4
Leucovorin
4
Lapatinib
4
Ipilimumab
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
temsirolimus
3
atezolizumab
3
abemaciclib
3
Trastuzumab
3
Radiotherapy
3
Radiation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
olaparib
×
Tumor-Agnostic
×
Clear all
NCT04801966
2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA
Terminated
3 enrolled
NCT02576444
2022-12-28
OLAPCO
Yale University
Phase 2
Terminated
67 enrolled
10 charts